Drug intelligence / Profile preview

Parvovax

Development stage: Unknown
Lead developer: ChoongAng Vaccine Laboratories
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

Parvovax is a veterinary vaccine specifically developed for companion animals. It was originally part of Merial's portfolio and was later divested to Ceva Santé Animale as a condition for regulatory approval of the business swap between Sanofi and Boehringer Ingelheim. The vaccine is designed to protect against parvovirus infection.

Brand names: Parvovax

Targets

Norovirus VP1

Beyond the preview

Go deeper on Parvovax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Parvovax.

Explore the full profile